Kyoritsu Co., Ltd. (7795) AI Stock Analysis

• Market Cap: ¥8.78B
• Dividend Yield: 3.98%
• Average Volume (3M): 192.31K
• Price to Earnings (P/E): 8.4
• Beta (1Y): 0.85
• Revenue Growth: 5.00%
• EPS Growth: 25.91%
• Country: JP
• Employees: 615
• Sector: Industrials
• Sector Strength: 72
• Industry: Conglomerates
• EPS (TTM): 11.31
• Shares Outstanding: 49,235,000
• 10 Day Avg. Volume: 122,930
• 30 Day Avg. Volume: 192,306
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥200.00
• Price Target Upside: -0.50% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 66 Neutral
• Price Target: ¥200.00 ▼(-0.50% Downside)

Kyoritsu Co., Ltd. demonstrates a stable financial foundation, with steady revenue growth and improving profitability contributing positively to its score. The technical analysis indicates a strong upward trend but warns of overbought conditions. The attractive valuation, with a low P/E ratio and high dividend yield, further supports the stock's appeal. Investors should be mindful of potential pullbacks due to technical overbought signals.

Kyoritsu Co., Ltd. Business Overview & Revenue Model

Company Description

Kyoritsu Co., Ltd. (7795) is a Japanese company primarily engaged in the development, manufacture, and sale of various healthcare and medical devices. The company operates in sectors including medical technology and equipment, providing high-quality products that cater to the needs of healthcare professionals and institutions. Its core products encompass a range of innovative medical devices designed to improve patient outcomes and enhance the efficiency of healthcare delivery.

How the Company Makes Money

Kyoritsu Co., Ltd. generates revenue through the sale of its medical devices and healthcare products to hospitals, clinics, and other medical institutions. The company focuses on leveraging its technological expertise to offer cutting-edge solutions that meet the evolving demands of the healthcare industry. Key revenue streams include direct sales to healthcare providers, partnerships with distributors, and collaborations with other companies in the medical technology sector. Additionally, Kyoritsu may engage in research and development initiatives to continually expand its product offerings and maintain competitiveness in the market.

Kyoritsu Co., Ltd. Financial Statement Overview

Summary

Kyoritsu Co., Ltd. presents a stable financial position with consistent revenue growth and improving profitability. The income statement reflects steady profitability with room for improvement. The balance sheet indicates manageable leverage, and cash flow analysis shows positive momentum. Attention to debt levels and profit margin enhancements could further strengthen financial health.

Income Statement

Kyoritsu Co., Ltd. shows a stable revenue stream with slight growth over the past few years. The gross profit margin is reasonable, and while the net profit margin is lower, it has improved recently. EBIT and EBITDA margins indicate efficient operations, although there was a dip in EBIT in earlier years. Overall, the income statement reflects steady profitability with room for improvement.

Balance Sheet

The company's balance sheet indicates a moderate debt-to-equity ratio, suggesting manageable leverage. Return on equity has improved, reflecting better profitability. The equity ratio shows a solid equity base, but there is a need for cautious debt management given the significant total debt levels.

Cash Flow

Cash flow analysis reveals a positive free cash flow growth trend. Operating cash flow to net income ratio is healthy, indicating good cash generation from operations. However, fluctuations in investing and financing cash flows highlight the need for careful cash management to sustain positive free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.35B	40.35B	40.02B	40.26B	37.80B	36.74B
Gross Profit	4.44B	4.37B	4.75B	4.55B	4.60B	3.85B
EBITDA	2.80B	2.92B	3.11B	2.59B	3.19B	474.17M
Net Income	714.88M	715.66M	907.68M	456.93M	-1.73M	-6.69M
Balance Sheet
Total Assets	42.27B	42.27B	42.81B	42.88B	676.14M	668.63M
Cash, Cash Equivalents and Short-Term Investments	9.22B	9.22B	12.56B	10.51B	12.94B	14.67B
Total Debt	13.78B	13.78B	14.50B	15.23B	15.76B	17.44B
Total Liabilities	24.63B	24.63B	25.80B	26.70B	130.31M	128.59M
Stockholders Equity	17.64B	17.64B	17.00B	16.17B	545.84M	540.03M
Cash Flow
Free Cash Flow	0.00	467.24M	3.35B	63.60M	-1.83B	-959.61M
Operating Cash Flow	0.00	1.20B	4.58B	1.02B	12.04M	-21.11M
Investing Cash Flow	0.00	-3.27B	-1.23B	-1.74B	-2.42B	-898.22M
Financing Cash Flow	0.00	-1.29B	-1.31B	-1.71B	-2.28B	-330.01M

Kyoritsu Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 201.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7795, the sentiment is Positive. The current price of 201 is below the 20-day moving average (MA) of 202.20, above the 50-day MA of 194.26, and above the 200-day MA of 171.75, indicating a neutral trend. The MACD of 1.72 indicates Positive momentum. The RSI at 53.54 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7795.

Kyoritsu Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3353	82 Outperform	¥10.73B	10.23	8.04%	3.22%	19.52%	-9.23%
7490	74 Outperform	¥9.10B	14.53	2.64%	1.91%	0.55%	95.43%
7670	71 Outperform	¥10.07B	5.58	8.33%	4.56%	-2.82%	18.67%
7795	66 Neutral	¥8.78B	8.41	―	3.98%	5.00%	25.91%
3004	66 Neutral	¥9.30B	5.20	15.04%	3.92%	2.65%	18.63%
3512	60 Neutral	¥11.14B	25.85	2.12%	3.13%	-5.08%	-3.36%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%